Researchers saw abbreviated overall survival times in estrogen receptor-positive metastatic breast cancer patients with ESR1 mutations in their cell-free DNA.
A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.
The Olivia Newton-John Cancer Research Institute in Melbourne received accreditation in Australia to perform mutation testing using Bio-Rad's droplet digital PCR.
Life Science segment sales grew 10 percent on a currency-neutral basis, benefiting in part from increased sales of Droplet Digital PCR products.
A prospective study used droplet digital PCR to search for treatment-informative EGFR and KRAS mutations in cell-free DNA from non-small cell lung cancer patients.
Bio-Rad reported $570.6 million in revenues in Q4, a 5 percent drop year over year but a 3 percent increase on a currency-neutral basis.
The consortium will analyze data from patients and mouse models in the first year as part of efforts to find ways of detecting tumors earlier.
Spokespersons from Bio-Rad noted that there appears to be an increasing number of researchers using ddPCR for methylation analyses.
The developers of the method are now using the ddPCR approach to create and test assays for early colon cancer detection.
Bio-Rad scientist Jennifer Berman explains how ddPCR can help detect the basic efficiency of CRISPR/Cas9 and other genome editing technologies and more.
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.